Literature DB >> 12350225

A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity.

Hidenori Kawashima1, Haruna Takano, Syozo Sugita, Yuki Takahara, Kazunobu Sugimura, Tatsuya Nakatani.   

Abstract

We have cloned a cDNA coding for a novel steroid receptor co-activator protein termed SRAP from a rat prostate library. Although the nucleotide sequence of the SRAP has 78.2% identity to that of the human steroid receptor RNA activator (SRA), a novel RNA molecule which was reported to act as an RNA transcript without being translated into protein [Lanz, McKenna, Onate, Albrecht, Wong, Tsai, Tsai and O'Malley (1999) Cell 97, 17-27], the cDNA of SRAP is capable of generating a functional protein. Glutathione S-transferase pull-down assays showed that SRAP associates with the partial androgen receptor (AR) protein composed of a DNA-binding domain and an activation function 2. Luciferase assays demonstrated that SRAP enhances the transactivation activity of the AR, the glucocorticoid receptor and the peroxisome proliferator-activated receptor gamma(1) in a ligand-dependent manner. Using a green fluorescent protein (GFP) fusion-protein construct, we demonstrated in vivo translation of the GFP-SRAP fusion protein in HeLa cells co-transfected with pSG5AR and reporter gene in the presence of 5 alpha-dihydrotestosterone (DHT). Co-transfection of the GFP-SRAP fusion protein expression plasmid enhanced the transactivation activity of AR whereas incorporation of mutations in SRAP of the fusion protein resulted in loss of enhancement of the transactivation activity. Northern blot analysis and reverse transcriptase PCR assays showed that SRAP and SRA are expressed in rat and human prostate cancer cell lines respectively. In HeLa cells and the human prostate cancer cells line DU-145, co-transfected with SRAP, the DHT-dependent transactivation activities of AR were not completely inhibited by the anti-androgen flutamide, but the transactivation activities still remained high even in the presence of 5 microM flutamide, suggesting that SRAP may play an important role in enhancing AR activity in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12350225      PMCID: PMC1223065          DOI: 10.1042/BJ20020743

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Altered expression of estrogen receptor coregulators during human breast tumorigenesis.

Authors:  L C Murphy; S L Simon; A Parkes; E Leygue; H Dotzlaw; L Snell; S Troup; A Adeyinka; P H Watson
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

2.  Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models.

Authors:  C Nessler-Menardi; I Jotova; Z Culig; I E Eder; T Putz; G Bartsch; H Klocker
Journal:  Prostate       Date:  2000-10-01       Impact factor: 4.104

3.  Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.

Authors:  R Eckner; M E Ewen; D Newsome; M Gerdes; J A DeCaprio; J B Lawrence; D M Livingston
Journal:  Genes Dev       Date:  1994-04-15       Impact factor: 11.361

4.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

Authors:  N Craft; Y Shostak; M Carey; C L Sawyers
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

5.  A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA.

Authors:  M Watanabe; J Yanagisawa; H Kitagawa; K Takeyama ; S Ogawa; Y Arao; M Suzawa; Y Kobayashi; T Yano; H Yoshikawa; Y Masuhiro; S Kato
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

6.  Androgen regulation by the long terminal repeat of mouse mammary tumor virus.

Authors:  P Darbre; M Page; R J King
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

7.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.

Authors:  T Chen; L H Wang; W L Farrar
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

8.  Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells.

Authors:  X Wang; S Yeh; G Wu; C L Hsu; L Wang; T Chiang; Y Yang; Y Guo; C Chang
Journal:  J Biol Chem       Date:  2001-08-16       Impact factor: 5.157

9.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

Authors:  J P Gaddipati; D G McLeod; H B Heidenberg; I A Sesterhenn; M J Finger; J W Moul; S Srivastava
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

10.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12
View more
  42 in total

1.  Regulated post-transcriptional RNA cleavage diversifies the eukaryotic transcriptome.

Authors:  Tim R Mercer; Marcel E Dinger; Cameron P Bracken; Gabriel Kolle; Jan M Szubert; Darren J Korbie; Marjan E Askarian-Amiri; Brooke B Gardiner; Gregory J Goodall; Sean M Grimmond; John S Mattick
Journal:  Genome Res       Date:  2010-11-02       Impact factor: 9.043

Review 2.  The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs.

Authors:  Xiangting Wang; Xiaoyuan Song; Christopher K Glass; Michael G Rosenfeld
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 3.  Non-coding RNAs: key regulators of mammalian transcription.

Authors:  Jennifer F Kugel; James A Goodrich
Journal:  Trends Biochem Sci       Date:  2012-02-01       Impact factor: 13.807

4.  Identification and expression of an encoding steroid receptor coactivator (SRA) in amphioxus (Branchiostoma japonicum).

Authors:  Huanhuan Sun; Lili Gao; Qiuxiang Pang; Lele Sun; Di Wu; Yun Bai; Bosheng Zhao; Juan Dong
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

Review 5.  Long noncoding RNAs: past, present, and future.

Authors:  Johnny T Y Kung; David Colognori; Jeannie T Lee
Journal:  Genetics       Date:  2013-03       Impact factor: 4.562

6.  Truncated SRA RNA derivatives inhibit estrogen receptor-α-mediated transcription.

Authors:  Euihan Jung; Seonghui Jang; Jungmin Lee; Youngmi Kim; Heegwon Shin; Hee-Sung Park; Younghoon Lee
Journal:  Mol Biol Rep       Date:  2016-07-12       Impact factor: 2.316

Review 7.  Long non-coding RNA regulation of reproduction and development.

Authors:  David H Taylor; Erin Tsi-Jia Chu; Roman Spektor; Paul D Soloway
Journal:  Mol Reprod Dev       Date:  2015-10-30       Impact factor: 2.609

Review 8.  Non-coding transcript variants of protein-coding genes - what are they good for?

Authors:  Sonam Dhamija; Manoj B Menon
Journal:  RNA Biol       Date:  2018-09-10       Impact factor: 4.652

9.  Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Authors:  Charlton Cooper; Jimin Guo; Yi Yan; Shilpa Chooniedass-Kothari; Florent Hube; Mohammad K Hamedani; Leigh C Murphy; Yvonne Myal; Etienne Leygue
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

10.  Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Authors:  Yi Yan; George P Skliris; Carla Penner; Shilpa Chooniedass-Kothari; Charlton Cooper; Zoann Nugent; Anne Blanchard; Peter H Watson; Yvonne Myal; Leigh C Murphy; Etienne Leygue
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.